KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to -$3.0 billion.

  • Eli Lilly's Cash from Investing Activities rose 2552.25% to -$3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 billion, marking a year-over-year increase of 208.63%. This contributed to the annual value of -$9.3 billion for FY2024, which is 3004.18% down from last year.
  • Latest data reveals that Eli Lilly reported Cash from Investing Activities of -$3.0 billion as of Q3 2025, which was up 2552.25% from -$1.8 billion recorded in Q2 2025.
  • Eli Lilly's Cash from Investing Activities' 5-year high stood at -$459.1 million during Q2 2023, with a 5-year trough of -$4.0 billion in Q3 2024.
  • For the 5-year period, Eli Lilly's Cash from Investing Activities averaged around -$1.6 billion, with its median value being -$1.2 billion (2024).
  • Per our database at Business Quant, Eli Lilly's Cash from Investing Activities soared by 4445.25% in 2023 and then crashed by 37891.53% in 2024.
  • Eli Lilly's Cash from Investing Activities (Quarter) stood at -$484.2 million in 2021, then plummeted by 94.86% to -$943.5 million in 2022, then tumbled by 209.94% to -$2.9 billion in 2023, then soared by 34.33% to -$1.9 billion in 2024, then crashed by 55.3% to -$3.0 billion in 2025.
  • Its last three reported values are -$3.0 billion in Q3 2025, -$1.8 billion for Q2 2025, and -$3.4 billion during Q1 2025.